This is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in NuCana plc (NASDAQ:NCNA) and Theravance Biopharma Inc. (NASDAQ:TBPH). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana plc	N/A	0.00	N/A	-0.60	0.00
Theravance Biopharma Inc.	60.37M	21.83	215.52M	-4.72	0.00

Table 1 demonstrates NuCana plc and Theravance Biopharma Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

	Net Margins	Return on Equity	Return on Assets
NuCana plc	0.00%	0%	0%
Theravance Biopharma Inc.	-357.00%	-520.6%	-60.6%

Liquidity

The Current Ratio and Quick Ratio of NuCana plc are 21.2 and 21.2 respectively. Its competitor Theravance Biopharma Inc.’s Current Ratio is 3.3 and its Quick Ratio is 3.1. NuCana plc can pay off short and long-term obligations better than Theravance Biopharma Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for NuCana plc and Theravance Biopharma Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
NuCana plc	0	0	0	0.00
Theravance Biopharma Inc.	0	0	2	3.00

Theravance Biopharma Inc. on the other hand boasts of a $47.5 average price target and a 102.21% potential upside.

Institutional and Insider Ownership

The shares of both NuCana plc and Theravance Biopharma Inc. are owned by institutional investors at 34.6% and 87.4% respectively. About 15.28% of NuCana plc’s share are owned by insiders. Insiders Comparatively, owned 5.7% of Theravance Biopharma Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
NuCana plc	9.97%	-0.46%	-30.08%	-45.98%	-29.7%	-11.03%
Theravance Biopharma Inc.	-0.37%	-6.1%	-8.46%	-14.12%	-7.96%	-4.42%

For the past year Theravance Biopharma Inc. has weaker performance than NuCana plc

Summary

NuCana plc beats Theravance Biopharma Inc. on 6 of the 10 factors.

NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer. The company is also developing NUC-3373, which is in Phase I clinical trials for the treatment of patients with advanced solid tumors, as well as for the treatment of colorectal and breast cancer; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematology. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. The company was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The companyÂ’s product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.